---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295106386.md"
description: "In Thursday's pre-market session, health care stocks showed significant volatility. Gainers included Creative Medical Tech (up 86.9%), Ensysce Biosciences (up 84.14%), and Insmed (up 24.81%). Losers featured Context Therapeutics (down 29.2%), Zhengye Biotechnology (down 27.97%), and BioVie (down 26.57%). Many price movements coincided with the release of recent quarterly earnings reports."
datetime: "2026-08-06T12:06:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295106386.md)
  - [en](https://longbridge.com/en/news/295106386.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295106386.md)
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Creative Medical Tech** (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million.
-   **Ensysce Biosciences** (NASDAQ:ENSC) shares moved upwards by 84.14% to $0.67. The market value of their outstanding shares is at $5.5 million.
-   **Insmed** (NASDAQ:INSM) stock rose 24.81% to $123.59. The market value of their outstanding shares is at $21.4 billion. As per the press release, Q2 earnings came out today.
-   **Pomdoctor** (NASDAQ:POM) stock increased by 23.52% to $0.86. The market value of their outstanding shares is at $83.4 million.
-   **Evolent Health** (NYSE:EVH) stock increased by 21.1% to $3.73. The market value of their outstanding shares is at $346.4 million. As per the press release, Q2 earnings came out today.
-   **Iovance Biotherapeutics** (NASDAQ:IOVA) shares moved upwards by 15.0% to $4.99. The company's market cap stands at $1.9 billion. As per the press release, Q2 earnings came out today.

### Losers

-   **Context Therapeutics** (NASDAQ:CNTX) stock fell 29.2% to $0.49 during Thursday's pre-market session. The company's market cap stands at $63.6 million. As per the press release, Q2 earnings came out yesterday.
-   **Zhengye Biotechnology** (NASDAQ:ZYBT) shares declined by 27.97% to $1.7. The company's market cap stands at $111.8 million.
-   **BioVie** (NASDAQ:BIVI) shares fell 26.57% to $1.5. The company's market cap stands at $15.3 million.
-   **BillionToOne** (NASDAQ:BLLN) stock decreased by 25.95% to $111.07. The market value of their outstanding shares is at $6.8 billion. As per the press release, Q3 earnings came out yesterday.
-   **SenesTech** (NASDAQ:SNES) stock declined by 23.32% to $1.25. The company's market cap stands at $8.6 million. As per the news, the Q2 earnings report came out yesterday.
-   **Akebia Therapeutics** (NASDAQ:AKBA) stock fell 23.05% to $0.99. The company's market cap stands at $346.0 million. As per the news, the Q2 earnings report came out yesterday. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [CELZ.US](https://longbridge.com/en/quote/CELZ.US.md)
- [ZYBT.US](https://longbridge.com/en/quote/ZYBT.US.md)
- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [POM.US](https://longbridge.com/en/quote/POM.US.md)
- [EVH.US](https://longbridge.com/en/quote/EVH.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [BLLN.US](https://longbridge.com/en/quote/BLLN.US.md)
- [SNES.US](https://longbridge.com/en/quote/SNES.US.md)
- [AKBA.US](https://longbridge.com/en/quote/AKBA.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [Insmed COO Roger Adsett sells 239,850 shares for $31.97 million](https://longbridge.com/en/news/295709972.md)
- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md)
- [BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration](https://longbridge.com/en/news/295718009.md)
- [Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation](https://longbridge.com/en/news/295574490.md)